ArticleEuropean journal of nuclear medicine and molecular imaging2019
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of [Frontiers in medicine · 2026Pooled it
- Bone Radiopharmaceuticals: Evolution from Palliative Therapy to Targeted Precision Oncology and Theranostics.Biology · 2026Review
- Evaluation of treatment efficacy of theEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Organ and tumor dosimetry of [European journal of nuclear medicine and molecular imaging · 2026Article
- Tolerability of [European journal of nuclear medicine and molecular imaging · 2026Article
- First-in-human tandem Terbium-161 and Actinium-225 PSMA radioligand therapy in metastatic castration-resistant prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.Nature reviews. Urology · 2026Review
- QuantitativeEJNMMI physics · 2026Article
- Preclinical Evaluation of 5T4-Targeted [Journal of medicinal chemistry · 2026Article
- Comparative theranostic efficacy ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Practical Aspects ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Fractionation gives therapeutic benefit in animal model of [EJNMMI research · 2026Article
- [Pharmaceutics · 2026Article
- Hydroxyquinoline-functionalised aza-crown macrocycles for lanthanide coordination.Dalton transactions (Cambridge, England : 2003) · 2026Article
- Auger Emitting [Nuclear medicine and molecular imaging · 2026Article
- Quantitative performance of a 3D CZT and conventional SPECT/CT for Tb-161 imaging.EJNMMI physics · 2026Article
- Head-to-head comparison of [EJNMMI research · 2026Article
- Tetrazine-Inorganic chemistry frontiers · 2026Article
- PSMA-targeted radioligand therapy with beta emitters in prostate cancer: current evidence, emerging indications, combination strategies, and future directions.Frontiers in medicine · 2026Review
- Recent Advances in Radiopharmaceuticals for Cancer Diagnosis and Therapy.Oncology research · 2026Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThe prostate-specific membrane antigen (PSMA) has emerged as an interesting target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). The aim of this study was to investigate
methods
results
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.